EMA Authorised: Prandin (repaglinide) — Novo Nordisk A/S

View source ↗

Summary

The EMA has authorised Prandin (repaglinide) for Type 2 diabetes, with Novo Nordisk A/S as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Prandin (repaglinide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novo Nordisk A/S. Decision date: 06/09/2017